Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Molecular Targeted Cancer Therapies Can anything else revolutionize the market

Molecular Targeted Cancer Therapies Can anything else revolutionize the market?

"IntroductionApproaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.ScopeResearch and analysis of the MTT pipeline with in-depth clinical and commercial assessment of Phase III candidates Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events Segmentation and examination of product pipeline by developmental phase, class, mode of action, indication and developer Insight and analysis of market potential including commercial opportunity, commonalities across cancers and discussion of unmet needsHighlights329 different pipeline candidates have been identified of which 24 are in late-phase development. These identified candidates have a forecast sales potential of up to $6.03 billion in the seven major pharmaceutical markets by 2016. Among agents with the greatest commercial potential are the angiogenesis inhibitors Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline). Other candidates holding particular promise include the only preregistered agent Novartis's Gleevec-follow-on Tasigna (nilotinib), Novartis's mTOR inhibitor Certican (everolimus), and Biogen Idec's anti-CD23 monoclonal antibody, lumiliximab.Reasons to PurchaseAcquire a detailed appreciation and impartial perspective of the entire molecular targeted therapies developmental pipeline Identify the key products in late-phase development based on sales forecasts to 2016 and Datamonitor's drug assessment methodology Assess the shifting oncology market dynamic and how future treatment of many cancers will incorporate pipeline products"

23-Oct-07 Format: PDF & SlidePack Pages: 434
Talble of Contents
Price: $15,200.00 / €10,168.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions